Skip to main content
  • HighLife welcomes Stefan Pilz as new Chief Executive Officer

    HighLife SAS, a leading MedTech company focusing on the development of a novel Trans-Septal Mitral Valve Replacement (“TMVR”) system to treat patients suffering from moderate to severe Mitral Regurgitation (MR), announced today the appointment of Stefan Pilz as the company’s new Chief Executive Officer, effective August 1st, 2024.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details